一、吡格列酮和/或生活方式宣教对非糖尿病的高甘油三酯血症人群胰岛素抵抗和胰岛细胞功能的影响——脂毒性2年前瞻性干预研究 二、基础胰岛素或每日两次预混胰岛素联合口服降糖药治疗的疗效和安全性比较
|
摘要
第一部分
吡格列酮和/或生活方式宣教对非糖尿病的高甘油三酯血症人群胰岛素抵抗和胰岛细胞功能的影响——脂毒性2年前瞻性干预研究
目的在有高甘油三酯(TG)血症的非糖尿病人群中进行生活方式宣教或生活方式宣教加口服胰岛素增敏剂吡格列酮干预2年,观察游离脂肪酸、胰岛素敏感性、胰岛功能、血糖的改变及相关心、脑血管疾病的危险因子(脂联素、TNF—α,尿微量白蛋白)变化,以探讨生活方式或同时加胰岛素增敏剂干预来预防脂毒性效果和方法。
方法采用前瞻性、随机、安慰剂对照的方法,选取无或仅有轻度糖代谢受损的非糖尿病的高TG血症(TG 2.26-4.52mmol/L)者,随机分为安慰剂对照组、生活方式宣教加安慰剂组、生活方式宣教加口服吡格列酮组(15mg/日),随访干预2年。定期测定体重、腰围、体脂百分含量,血FFA、脂联素、TNF—α、尿微量白蛋白/尿肌酐比值(UACR),每年进行一次OGTT。
结果共有97例入选本研究,66例完成2年随访。2年时吡格列酮干预组FFA低于对照组[0.30mmol/L(0.20-0.45)vs 0.43mmol/L(0.40-0.59):P＜0.05],内脏脂肪减少(腰围、腰围/臀围下降均大于对照组),脂联素高于对照组[7216ng/ml(4234-9261)vs 3882ng/ml(2654-5746):P＜0.05],TNF-α低于对照组[6.38pg/ml(3.32-8.26)vs 12.87pg/ml(9.16-20.31),P＜0.01],UACR低于对照组[0.31mg/mmol(0.10—0.91)vs 2.28 mg/mmol(1.12—4.01),P＜0.01],HOMA-IR较基线的增加小于对照组(0.08±0.33 vs 1.20±0.38,P＜0.05),OGTT早时相胰岛素分泌显著改善(0.5h胰岛素水平高于对照组:102.40±14.49uiu/ml vs 68.13±7.65 uiu/ml,早时相胰岛素分泌指数大于对照组:INS(30-0)min/BG(30-0)min 24.67±3.63 vs 14.16±2.05;P均＜0.05)。单纯生活方式宣教组血脂、腰围、脂联素、UACR等指标有一些有益的改变,但变化较小。多因素分析提示干预后血FFA的变化和是否服用吡格列酮治疗是决定其早时相胰岛素分泌改善的最重要指标。
结论在非糖尿病的高TG血症人群应用吡格列酮可能通过改善脂肪组织功能来降低FFA水平,升高脂联素、降低TNF-α等途径改善胰岛素敏感性和β细胞功能,并进一步降低糖尿病和心血管疾病发生风险。单纯生活方式宣教干预力度较弱且难以持久。
第二部分
基础胰岛素或每日两次预混胰岛素联合口服降糖药治疗的疗效和安全性比较
目的比较每日注射两次预混胰岛素血糖控制不理想的2型糖尿病患者转为每日注射一次甘精胰岛素加格列美脲或每日注射两次预混胰岛素加格列美脲的血糖控制和低血糖发生情况。
方法为随机、开放、两中心的平行对照研究,治疗期12周,选择每日注射两次预混胰岛素(加或不加口服降糖药治疗),空腹血糖(FBG)在7.8～16.7mmol/L,HbAlc在7%～10%的2型糖尿病患者80例,随机分至每日注射一次甘精胰岛素加格列美脲3mg或每日注射两次预混诺和灵30R胰岛素加格列美脲3mg治疗组,胰岛素剂量每3天调整一次,至目标FBG≤6.0mmol/L。
结果治疗12周后,甘精胰岛素组和预混胰岛素组的HbAlc均较基线水平显著下降,两组HbAlc下降幅度无差异(8.8%→8.0%vs 8.9%→7.8%,P=NS)。治疗期间,预混胰岛素组低血糖发生频率均显著高于甘精胰岛素组(总低血糖事件:123次vs 57次,经证实的低血糖例次(94(76%)vs 21(47%),x~2=23.692 P=0),其中午餐前低血糖发生尤其显著(64(52%)vs 17(30%)x~2=7.762 P=0.005)。甘精胰岛素治疗后HbAlc≤7.5%者达28.2%(11例),胰岛素剂量为0.58±0.29u.kg~(-1).d~(-1);HbAlc＞8.5%者占23.1%(9例),胰岛素剂量为0.66±0.30u.kg~(-1).d~(-1)。甘精胰岛素上述两亚组治疗前HbAlc、糖尿病病程、标准餐后2hC肽水平差异均有显著性[分别为:8.1%±0.8%vs 9.6%±1.2%,10年(6年～14.5年)vs 13年(8年～19.5年),餐后C肽:2.5nmol/L(1.4 nmol/L～3.3 nmol/L)vs 1.4nmol/L(1.2 nmol/L～2.6 nmol/L),p值均＜0.05]。
结论在本组2型糖尿病患者中,每日注射一次甘精胰岛素联合口服降糖药和每日注射两次预混胰岛素联合口服降糖药相比可以达到同样的血糖控制效果,并且低血糖发生率相对少。治疗前HbAlc水平、糖尿病病程和餐后2h C肽水平是影响一次基础胰岛素联合口服降糖药治疗疗效的主要指标。
OBJECTIVE—To explore the effects and strategies of lifestyle or/and pioglitazone intervention on lipotoxicity.
RESEARCH DESIGN and METHODS—Nondiabetic subjects with hypertriglyceridaemia(TG 2.26-4.52mmol/L) were randomly assigned to receive one tablet of placebo(CON) or diet and exercise education plus one tablet of placebo(LIF),or diet and exercise education plus 15 mg/day pioglitazone(PIO) for 24months.Before and during the intervention,body composition,body fat distribution[waist circumference(WR),waist-to-hip ratio(WHR)],plasma adiponectin,plasma TNF-α,urine albumin/creatine ratio(UACR),insulin sensitivity andβcell function were assessed.
RESULTS—We enrolled 97subjects in this study[baseline data:BMI 26.8±3.1 kg/m~2,WHR 0.97±0.04,FFA 0.5mmol/L(0.4—0.7),TG 2.93mmol/L(2.51—3.49)], 66subjects completed this 2-year study.At the end of the second year,compared with CON group,FFA in PIOgroup were significantly lower[0.30mmol/L(0.20-0.45) vs 0.43mmol/L(0.40-0.59);P＜0.05];WR and WHR decreased larger;plasma adiponectin were higher[7216ng/ml(4234～9261) vs 3882ng/ml(2654～5746);P＜0.05];plasma TNF—αwere lower(6.38pg/ml(3.32～8.26) vs 12.87pg/ml(9.16～20.31),P＜0.01), UACR were lower(0.31mg/mmol(0.10～0.91) vs 2.28 mg/mmol(1.12～4.01), P＜0.01)、HOMA—IR increment from baseline were smaller(0.08±0.33 vs 1.20±0.38,P＜0.05),early insulin secretion response increased larger(0.5h—insulin in OGTT:102.40±14.49uiu/ml vs 68.13±7.65 uiu/ml, iNS(30-0)min/BG(30-0)min(IGR):24.67±3.63 vs 14.16±2.05;all P＜0.05)。The decrease in plasma FFA was strongly and independently associated with IGR2y.Some of the above parameters ameliorated in LIF group,but the degree was limited and couldn't last very long.
CONCLUSIONS—We show for the first time that pioglitazone used in nondiabetic subjects with hypertriglyceridaemia can decrease FFA by improving adipose tissue function,induce increase in serum adiponectin,decrease in TNF-αand UACR.All these factors contribute to amelioration of insulin resistance andβcell function.And may predict the reduction in incidence of diabetes and risk of future cardiovascular disease.
OBJECTIVE- To compare the efficacy and safety of glargine or premixed insulin twice daily in combination with glimepiride in Type 2 Diabetes.
RESEARCH DESIGN AND METHODS-In a 12-week,two-center,open,parallel group clinical trial,80 type 2 diabetic patients treated with twice-daily premixed 30R insulin with or without OAD(s)(fasting blood glucose[FBG]7.8 mmol/L～16.7mmol/L,HbA1c7%～10%) were randomized to once-daily morning insulin glargine plus glimepiride 3mg or premixed 30R insulin(70/30) twice-daily plus glimepiride 3mg.Insulin dosage was titrated to target FBG≤6.0mmol/L using a three-day forced-titration algorithm.
RESULTS-Mean HbA1c reduction from baseline were similar in glargine group and premixed insulin group(8.8%→8.0%vs 8.9%→7.8%,P=NS).However, hypoglycemic episodes were significantly higher in premixed-insulin-treated subjects than in glargine-treated subjects,(total:123 vs 57;proved hypoglycemic episodes (94(76%) vs 21(47%),χ~2=23.692 P＜0.001),The frequency of hypoglycemia before lunch was especially greater in premixed-insulin-treated subjects(64(52%) vs 17(30%)χ~2=7.762 P=0.005).Several subjects from the premixed arm experienced too frequent hypoglycemic episodes to be recorded during 10AM～11AM almost every day.Subgroup analysis for patients treated with glargine:28.2%(11 cases) of the patients in this subgroup attained HbA1c≤7.5%.Mean daily dosage for glargine at 12w were 0.58±0.29 u.kg~(-1).d~(-1) in this subgroup.23.1%(9 cases) patients with HbA1c＞8.5%,mean daily dosage for glargine were 0.66±0.30 u.kg~(-1).d~(-1) at 12w. There were significant differences of baseline HbA1c,diabetes duration and baseline postprandial C-peptide between the two subgroups in glargine arm(HbA1c:8.1%±0.8%vs 9.6%±1.2%;duration:10years(6～14.5) vs 13years(8～19.5);postprandial c peptide:2.5nmol/L(1.4～3.3) vs 1.4nmol/L(1.2～2.6),all P＜0.05).
CONCLUSIONS-Some type 2 diabetic patients treated with twice-daily injection of 70/30 with or without OAD(s) can be effectively and safely switched to basal insulin plus OAD.Pretreatment HbA1c,diabetes duration and postprandial C peptide are the key factors that closely related to efficacy of this new regimen.
吡格列酮和/或生活方式宣教对非糖尿病的高甘油三酯血症人群胰岛素抵抗和胰岛细胞功能的影响——脂毒性2年前瞻性干预研究
目的在有高甘油三酯(TG)血症的非糖尿病人群中进行生活方式宣教或生活方式宣教加口服胰岛素增敏剂吡格列酮干预2年,观察游离脂肪酸、胰岛素敏感性、胰岛功能、血糖的改变及相关心、脑血管疾病的危险因子(脂联素、TNF—α,尿微量白蛋白)变化,以探讨生活方式或同时加胰岛素增敏剂干预来预防脂毒性效果和方法。
方法采用前瞻性、随机、安慰剂对照的方法,选取无或仅有轻度糖代谢受损的非糖尿病的高TG血症(TG 2.26-4.52mmol/L)者,随机分为安慰剂对照组、生活方式宣教加安慰剂组、生活方式宣教加口服吡格列酮组(15mg/日),随访干预2年。定期测定体重、腰围、体脂百分含量,血FFA、脂联素、TNF—α、尿微量白蛋白/尿肌酐比值(UACR),每年进行一次OGTT。
结果共有97例入选本研究,66例完成2年随访。2年时吡格列酮干预组FFA低于对照组[0.30mmol/L(0.20-0.45)vs 0.43mmol/L(0.40-0.59):P＜0.05],内脏脂肪减少(腰围、腰围/臀围下降均大于对照组),脂联素高于对照组[7216ng/ml(4234-9261)vs 3882ng/ml(2654-5746):P＜0.05],TNF-α低于对照组[6.38pg/ml(3.32-8.26)vs 12.87pg/ml(9.16-20.31),P＜0.01],UACR低于对照组[0.31mg/mmol(0.10—0.91)vs 2.28 mg/mmol(1.12—4.01),P＜0.01],HOMA-IR较基线的增加小于对照组(0.08±0.33 vs 1.20±0.38,P＜0.05),OGTT早时相胰岛素分泌显著改善(0.5h胰岛素水平高于对照组:102.40±14.49uiu/ml vs 68.13±7.65 uiu/ml,早时相胰岛素分泌指数大于对照组:INS(30-0)min/BG(30-0)min 24.67±3.63 vs 14.16±2.05;P均＜0.05)。单纯生活方式宣教组血脂、腰围、脂联素、UACR等指标有一些有益的改变,但变化较小。多因素分析提示干预后血FFA的变化和是否服用吡格列酮治疗是决定其早时相胰岛素分泌改善的最重要指标。
结论在非糖尿病的高TG血症人群应用吡格列酮可能通过改善脂肪组织功能来降低FFA水平,升高脂联素、降低TNF-α等途径改善胰岛素敏感性和β细胞功能,并进一步降低糖尿病和心血管疾病发生风险。单纯生活方式宣教干预力度较弱且难以持久。
第二部分
基础胰岛素或每日两次预混胰岛素联合口服降糖药治疗的疗效和安全性比较
目的比较每日注射两次预混胰岛素血糖控制不理想的2型糖尿病患者转为每日注射一次甘精胰岛素加格列美脲或每日注射两次预混胰岛素加格列美脲的血糖控制和低血糖发生情况。
方法为随机、开放、两中心的平行对照研究,治疗期12周,选择每日注射两次预混胰岛素(加或不加口服降糖药治疗),空腹血糖(FBG)在7.8～16.7mmol/L,HbAlc在7%～10%的2型糖尿病患者80例,随机分至每日注射一次甘精胰岛素加格列美脲3mg或每日注射两次预混诺和灵30R胰岛素加格列美脲3mg治疗组,胰岛素剂量每3天调整一次,至目标FBG≤6.0mmol/L。
结果治疗12周后,甘精胰岛素组和预混胰岛素组的HbAlc均较基线水平显著下降,两组HbAlc下降幅度无差异(8.8%→8.0%vs 8.9%→7.8%,P=NS)。治疗期间,预混胰岛素组低血糖发生频率均显著高于甘精胰岛素组(总低血糖事件:123次vs 57次,经证实的低血糖例次(94(76%)vs 21(47%),x~2=23.692 P=0),其中午餐前低血糖发生尤其显著(64(52%)vs 17(30%)x~2=7.762 P=0.005)。甘精胰岛素治疗后HbAlc≤7.5%者达28.2%(11例),胰岛素剂量为0.58±0.29u.kg~(-1).d~(-1);HbAlc＞8.5%者占23.1%(9例),胰岛素剂量为0.66±0.30u.kg~(-1).d~(-1)。甘精胰岛素上述两亚组治疗前HbAlc、糖尿病病程、标准餐后2hC肽水平差异均有显著性[分别为:8.1%±0.8%vs 9.6%±1.2%,10年(6年～14.5年)vs 13年(8年～19.5年),餐后C肽:2.5nmol/L(1.4 nmol/L～3.3 nmol/L)vs 1.4nmol/L(1.2 nmol/L～2.6 nmol/L),p值均＜0.05]。
结论在本组2型糖尿病患者中,每日注射一次甘精胰岛素联合口服降糖药和每日注射两次预混胰岛素联合口服降糖药相比可以达到同样的血糖控制效果,并且低血糖发生率相对少。治疗前HbAlc水平、糖尿病病程和餐后2h C肽水平是影响一次基础胰岛素联合口服降糖药治疗疗效的主要指标。
OBJECTIVE—To explore the effects and strategies of lifestyle or/and pioglitazone intervention on lipotoxicity.
RESEARCH DESIGN and METHODS—Nondiabetic subjects with hypertriglyceridaemia(TG 2.26-4.52mmol/L) were randomly assigned to receive one tablet of placebo(CON) or diet and exercise education plus one tablet of placebo(LIF),or diet and exercise education plus 15 mg/day pioglitazone(PIO) for 24months.Before and during the intervention,body composition,body fat distribution[waist circumference(WR),waist-to-hip ratio(WHR)],plasma adiponectin,plasma TNF-α,urine albumin/creatine ratio(UACR),insulin sensitivity andβcell function were assessed.
RESULTS—We enrolled 97subjects in this study[baseline data:BMI 26.8±3.1 kg/m~2,WHR 0.97±0.04,FFA 0.5mmol/L(0.4—0.7),TG 2.93mmol/L(2.51—3.49)], 66subjects completed this 2-year study.At the end of the second year,compared with CON group,FFA in PIOgroup were significantly lower[0.30mmol/L(0.20-0.45) vs 0.43mmol/L(0.40-0.59);P＜0.05];WR and WHR decreased larger;plasma adiponectin were higher[7216ng/ml(4234～9261) vs 3882ng/ml(2654～5746);P＜0.05];plasma TNF—αwere lower(6.38pg/ml(3.32～8.26) vs 12.87pg/ml(9.16～20.31),P＜0.01), UACR were lower(0.31mg/mmol(0.10～0.91) vs 2.28 mg/mmol(1.12～4.01), P＜0.01)、HOMA—IR increment from baseline were smaller(0.08±0.33 vs 1.20±0.38,P＜0.05),early insulin secretion response increased larger(0.5h—insulin in OGTT:102.40±14.49uiu/ml vs 68.13±7.65 uiu/ml, iNS(30-0)min/BG(30-0)min(IGR):24.67±3.63 vs 14.16±2.05;all P＜0.05)。The decrease in plasma FFA was strongly and independently associated with IGR2y.Some of the above parameters ameliorated in LIF group,but the degree was limited and couldn't last very long.
CONCLUSIONS—We show for the first time that pioglitazone used in nondiabetic subjects with hypertriglyceridaemia can decrease FFA by improving adipose tissue function,induce increase in serum adiponectin,decrease in TNF-αand UACR.All these factors contribute to amelioration of insulin resistance andβcell function.And may predict the reduction in incidence of diabetes and risk of future cardiovascular disease.
OBJECTIVE- To compare the efficacy and safety of glargine or premixed insulin twice daily in combination with glimepiride in Type 2 Diabetes.
RESEARCH DESIGN AND METHODS-In a 12-week,two-center,open,parallel group clinical trial,80 type 2 diabetic patients treated with twice-daily premixed 30R insulin with or without OAD(s)(fasting blood glucose[FBG]7.8 mmol/L～16.7mmol/L,HbA1c7%～10%) were randomized to once-daily morning insulin glargine plus glimepiride 3mg or premixed 30R insulin(70/30) twice-daily plus glimepiride 3mg.Insulin dosage was titrated to target FBG≤6.0mmol/L using a three-day forced-titration algorithm.
RESULTS-Mean HbA1c reduction from baseline were similar in glargine group and premixed insulin group(8.8%→8.0%vs 8.9%→7.8%,P=NS).However, hypoglycemic episodes were significantly higher in premixed-insulin-treated subjects than in glargine-treated subjects,(total:123 vs 57;proved hypoglycemic episodes (94(76%) vs 21(47%),χ~2=23.692 P＜0.001),The frequency of hypoglycemia before lunch was especially greater in premixed-insulin-treated subjects(64(52%) vs 17(30%)χ~2=7.762 P=0.005).Several subjects from the premixed arm experienced too frequent hypoglycemic episodes to be recorded during 10AM～11AM almost every day.Subgroup analysis for patients treated with glargine:28.2%(11 cases) of the patients in this subgroup attained HbA1c≤7.5%.Mean daily dosage for glargine at 12w were 0.58±0.29 u.kg~(-1).d~(-1) in this subgroup.23.1%(9 cases) patients with HbA1c＞8.5%,mean daily dosage for glargine were 0.66±0.30 u.kg~(-1).d~(-1) at 12w. There were significant differences of baseline HbA1c,diabetes duration and baseline postprandial C-peptide between the two subgroups in glargine arm(HbA1c:8.1%±0.8%vs 9.6%±1.2%;duration:10years(6～14.5) vs 13years(8～19.5);postprandial c peptide:2.5nmol/L(1.4～3.3) vs 1.4nmol/L(1.2～2.6),all P＜0.05).
CONCLUSIONS-Some type 2 diabetic patients treated with twice-daily injection of 70/30 with or without OAD(s) can be effectively and safely switched to basal insulin plus OAD.Pretreatment HbA1c,diabetes duration and postprandial C peptide are the key factors that closely related to efficacy of this new regimen.
引文
1 Boden G.Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.Diabetes JT-Diabetes,1997,46(1):3-10.
2 Miles JM,Nelson RH.Contribution of triglyceride-rich lipoproteins to plasma free fatty acids.Horm Metab Res JT-Hormoneand metabolic research.Hormon-und Stoffwechselforschung.Hormones et metabolisme,2007,39(10):726-9.
3 Mostaza JM,Vega GL,Snell P,et al.Abnormal metabolism of free fatty acids in hypertriglyceridaemic men:apparent insulin resistance of adipose tissue.J Intern Med JT -Journal of internal medicine,1998,243(4):265-74.
4 Siiteri PK.Adipose tissue as a source of hormones.Am J Clin Nutr JT-The American journal of clinical nutrition,1987,45(1 Suppl):277-82.
5 Fruhbeck G,Gomez-Ambrosi J,Muruzabal FJ,et al.The adipocyte:a model for integration of endocrine and metabolic signaling in energy metabolism regulation.Am J Physiol Endocrinol Metab JT-American journal of physiology.Endocrinology and metabolism,2001,280(6):E827-47.
6 Dobbins RL,Chester,,Daniels MB,et al.Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans.Diabetes JT-Diabetes,1998,47(10):1613-8.
7 Boden G,Chen X,Iqbal N.Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.Diabetes JT-Diabetes,1998,47(10):1609-12.
8 Trayhurn P,Wood IS.Adipokines:inflammation and the pleiotropic role of white adipose tissue.Br J Nutr JT-The British journal of nutrition,2004,92(3):347-55.
9 Paolisso G,Tataranni PA,Foley JE,et al.A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.Diabetologia JT -Diabetologia,1995,38(10):1213-7.
10 Chen X,Iqbal N,Boden G.The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects.J Clin Invest JT-The Journal of clinical investigation,1999,103(3):365-72.
11 Eorpeleijn E,Mensink M,Kooi ME,et al.Impaired Skeletal Muscle Substrate Oxidation in Glucose-intolerant Men Improves After Weight Loss.Obesity(Silver Spring) JT-Obesity (Silver Spring,Md.),2008.
12 Jensen MD,Haymond MW,Rizza RA,et al.Influence of body fat distribution on free fatty acid metabolism in obesity.J Clin Invest JT-The Journal of clinical investigation,1989,83(4):1168-73.
13 杨文英,邢小燕,林红等.高甘油三酯血症是非胰岛素依赖型糖尿病发病的危险因素-432例非糖尿病人群六年前瞻性观察.中华内科杂志,1995,34:583-586.
14 Grundy SM.Obesity,metabolic syndrome,and cardiovascular disease.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2004,89(6):2595-600.
15 Wajchenberg BL.Subcutaneous and visceral adipose tissue:their relation to the metabolic syndrome.Endocr Rev JT-Endocrine reviews,2000,21(6):697-738.
16 Hallakou S,Ooare L,Foufelle F,et al.Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.Diabetes JT-Diabetes,1997,46(9):1393-9.
17 Wang B,Li HL,Yang WY.Effect of lipid infusion on the function of islet β cells and gene expression of insulin signal transduction system.Beijing Da Xue Xue Bao,2007,39(5):462-466.
18 卜石,杨文英,王昕等.长期高脂饲养对大鼠葡萄糖刺激的胰岛素分泌的影响.中华内分泌代谢杂志,2003,19(1):25-28.
19 白秀平,李宏亮,杨文英等.脂肪分存的顺序及其与胰岛素抵抗的关系.中华内分泌代谢杂志,2007,23(4):307-310.
20 赵文惠,萧建中,杨文英等.高脂饲养及罗格列酮干预对大鼠胰岛素信号系统基因表达的影响.中国糖尿病杂志,2007,15(3):180-183.
21 陈晓平,杨文英,萧建中等.马来酸罗格列酮干预高脂饲养大鼠脂肪肝的研究.中国糖尿病杂志,2006,14(5):380-382.
22 Koh EH,Kim MS,Park JY,et al.Peroxisome proliferator-activated receptor(PPAR)-alpha activation prevents diabetes in OLETF rats:comparison with PPAR-gamma activation.Diabetes JT-Diabetes,2003,52(9):2331-7.
23 Phillips DI,Clark PM,Hales CN,et al.Understanding oral glucose tolerance:comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.Diabet Med JT-Diabetic medicine:a journal of the British Diabetic Association,1994,11(3):286-92.
24 Alberti KG,Zimmet P,Shaw J.The metabolic syndrome-a new worldwide definition.Lancet JT-Lancet,2005,366(9491):1059-62.
25 Fernandez-Real JM,Lopez-Bermejo A,Casamitjana R,et al.Novel interactions of adiponectin with the endocrine system and inflammatory parameters.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2003,88(6):2714-8.
26 Gerstein HC,Yusuf S,Bosch J,et al.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:a randomised controlled trial.Lancet JT-Lancet,2006,368(9541):1096-105.
27 Mayerson AB,Hundal RS,Dufour S,et al.The effects of rosiglitazone on insulin sensitivity,lipolysis,and hepatic and skeletal muscle triglyceride content in patients with type 2diabetes.Diabetes JT-Diabetes,2002,51(3):797-802.
28 Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2002,87(6):2784-91.
29 de Souza CJ,Eckhardt M,Gagen K,et al.Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.Diabetes JT-Diabetes,2001,50(8):1863-71.
30 Miyazaki Y,Mahankali A,Wajcberg E,et al.Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2004,89(9):4312-9.
31 Serlie MJ,Allick G,Groener JE,et al.Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type Ⅱ from free fatty acid-induced insulin resistance.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2007,92(1):166-71.
32 Mori Y,Murakawa Y,Okada K,et al.Effect of troglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care JT-Diabetes care,1999,22(6):908-12.
33 Laplante M,Festuccia WT,Soucy G,et al.Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.Diabetes JT- Diabetes, 2006,55(10): 2771-8.
34 Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care JT - Diabetes care, 2004,27(7): 1660-7.
35 Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism JT - Metabolism: clinical and experimental, 2005,54(1):24-32.
36 Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care JT - Diabetes care, 2003,26(11) :3148-52.
37 Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2005,288(5) :E930-4.
38 Dietze-Schroeder D, Sell H, Uhlig M, et al. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes JT - Diabetes, 2005,54(7): 2003-11.
39 Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2001,98(4):2005-10.
40 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation JT - Circulation, 1999,100(25): 2473-6.
41 Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes JT -Diabetes, 2007, 56(5): 1387-94.
42 Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation JT -Circulation, 2000, 102(11): 1296-301.
43 Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes JT - Diabetes, 2002,51 (6): 1884-8.
44 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes JT - Diabetes, 2001,50(5): 1126-33.
45 Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(4):1907-10.
46 Chandran M, Phillips SA, Ciaraldi T. et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care JT - Diabetes care, 2003, 26(8): 2442-50.
47 Weiss R, Dufour S, Groszmann A, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(5):2014-8.
48 Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes JT - Diabetes, 2003,52(7): 1655-63.
49 Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest JT -The Journal of clinical investigation, 1998,101(6):1354-61.
50 Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004,89(1):200-6.
51 Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med JT - Nature medicine, 2002,8(11): 1288-95.
52 Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest JT - The Journal of clinical investigation, 1997,100(7): 1863-9.
53 Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008.
54 Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol JT - Journal of the American College of Cardiology, 2006, 48(7):1369-77.
55 Maegawa H, Nishio Y, Nakao K, et al. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J JT - Endocrine journal, 2007,54(4) :613-8.
56 Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology, 2005,25(10): 2062-8.
57 Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator—activated receptor-gamma. Diabetes JT - Diabetes, 2001,50(5): 1083-92.
58 Martens FM, Rabelink TJ, op't Roodt J, et al. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J JT - European heart journal, 2006, 27(13): 1605-9.
59 Shimizu H, Oh-I S, Tsuchiya T, et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2006, 23(3): 253-7.
60 Shibasaki M, Takahashi K, Itou T, et al. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun JT - Biochemical and biophysical research communications, 2003, 309(2):419-24.
61 Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes JT -Diabetes, 2005,54(8): 2305-13.
62 Cerasi E, Luft R, Efendic S. Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes JT -Diabetes, 1972, 21 (4): 224-34.
63 O'Rahilly SP, Nugent Z, Rudenski AS, et al. Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet JT - Lancet, 1986, 2(8503): 360-4.
64 Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA JT - JAMA : the journal of the American Medical Association, 1995, 273(23): 1855-61.
65 Yoneda H, Ikegami H, Yamamoto Y, et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care JT - Diabetes care, 1992, 15(11): 1517-21.
66 Pimenta W, Mitrakou A, Jensen T, et al. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 1996,13(9 Suppl 6):S33-6.
67 Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care JT - Diabetes care, 1997, 20(10): 1562-8.
68 Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1994,91(23):10878-82.
69 Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1997,94(9):4637-41.
70 Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and Somatostatin levels. J Biol Chem JT -The Journal of biological chemistry, 1997, 272(48):30261-9.
71 Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes JT - Diabetes, 2001,50(5): 1021-9.
72 Matsui J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes JT -Diabetes, 2004, 53(11):2844-54.
73 Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology JT -Endocrinology, 2001,142(3): 1269-77.
74 Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2004, 286(4):E560-7.
75 Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care JT - Diabetes care, 2004,27(11) :2585-9.
76 Racette SB, Davis AO, McGill JB, et al. Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism JT - Metabolism: clinical and experimental, 2002, 51(2): 169-74.
77 Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia JT - Diabetologia, 2001,44(12):2210-9.
78 Furtner M, Kiechl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J JT - European heart journal, 2005, 26(3):279-87.
79 Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet JT -Lancet, 1992, 340(8815): 319-23.
80 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia JT -Diabetologia, 1989, 32(4): 219-26.
81 Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation JT - Circulation, 2002,106(14): 1777-82.
82 Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care JT - Diabetes care, 2006, 29 (3): 595-600.
83 Duman D, Demirtunc R, Karadag B, et al. Association of albuminuria with impaired aortic elasticity and left ventricular diastolic dysfunction in type 2 diabetes. Anadolu Kardiyol Derg JT - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2008,8(1): 10-5.
84 Sung KC, Kim BJ, Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis JT - Atherosclerosis, 2008,196(1) :320-6.
85 Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med JT - Archives of internal medicine, 1997,157(13):1413-8.
86 Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation JT -Circulation, 2005, 112(7):969-75.
87 Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation JT - Circulation, 2004,110(1):32-5.
88 Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens JT - Journal of hypertension, 2004,22(9):1805-11.
89 Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension JT - Hypertension, 2005,45(2):198-202.
90 Lu B, Wen J, Song XY, et al. High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract JT -Diabetes research and clinical practice, 2007,75(2):184-92.
91 Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes JT - Diabetes, 2002, 51 (4): 1157-65.
92 Kshirsagar AV, Bomback AS, Bang H, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol JT - The American journal of cardiology, 2008,101(3):401-6.
93 Perticone F, Maio R, Tripepi G, et al. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol JT - Journal of nephrology, 2007, 20 Suppl 12:S56-62.
94 Ferroni P, Guagnano MT, Falco A, et al. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond) JT -Clinical science (London, England : 1979), 2008,114(6):449-55.
95 Festa A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int JT - Kidney international, 2000, 58(4): 1703-10.
96 Nakamura M, Onoda T, Itai K, et al. Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med JT - Internal medicine (Tokyo, Japan), 2004, 43(10):919-25.
97 Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA JT - JAMA : the journal of the American Medical Association, 2001, 286(4):421-6.
98 Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care JT - Diabetes care, 2006, 29(5): 1039-45.
99 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med JT - The New England journal of medicine, 2002, 346(6):393-403.
100 Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med JT - The New England journal of medicine, 2001, 344(18):1343-50.
101 Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes JT -Diabetes, 2002, 51 (9): 2796-803.
102 Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes JT - Diabetes, 2005,54(4): 1150-6.
103 Moore GB, Pickavance LC, Briscoe CP, et al. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2008,10(3):251-63.
104 Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2007, 76(2):279-89.
105 Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes JT - Diabetes, 2005, 54(8):2404-14.
106 Kim ES, Im JA, Kim KC, et al. Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity (Silver Spring) JT - Obesity (Silver Spring, Md.), 2007,15(12): 3023-30.
107 Bluher M, Bullen JW Jr, Lee JH, et al. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2006,91(6):2310-6.
108 Bluher M, Williams CJ, Kloting N, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care JT - Diabetes care, 2007, 30(12) :3110-5.
109 Rasmussen MS, Lihn AS, Pedersen SB, et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) JT -Obesity (Silver Spring, Md.), 2006, 14(1) :28-35.
110 Hulver MW, Zheng D, Tanner CJ, et al. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2002, 283(4) :E861-5.
111 Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care JT - Diabetes care, 2003, 26(8):2383-8.
112 Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004, 89 (6): 2697-703.
113 Arai K, Soga T, Ohata H, et al. Effects of food restriction on peroxisome proliferator-activated receptor-gamma and glucocorticoid receptor signaling in adipose tissues of normal rats. Metabolism JT - Metabolism: clinical and experimental, 2004,53(1) :28-36.
114 Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2001, 86(8):3815-9.
115 Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2008,158(2):179-87.
116 The Diabetes Prevention Program.Design and methods for a clinical trial in the prevention of type 2 diabetes.Diabetes Care JT-Diabetes care,1999,22(4):623-34.
1 Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets JT - Current drug targets, 2004, 5(3):241-50.
2 Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr JT - The American journal of clinical nutrition, 1987,45(1 Suppl):277-82.
3 Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature JT -Nature, 1994,372(6505): 425-32.
4 Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2001, 280 (6): E827-47.
5 Frayn KN, Karpe F, Fielding BA, et al. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, 27 (8): 875-88.
6 Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest JT - Journal of endocrinological investigation, 2002, 25(10):823-35.
7 Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature JT -Nature, 2001, 409(6818): 307-12.
8 Bruun JM, Stallknecht B, Helge JW, et al. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2007,157(4):465-71.
9 Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology JT -Endocrinology, 2004,145(5):2273-82.
10 Van Harmelen V, Reynisdottir S, Eriksson P, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes JT - Diabetes, 1998,47(6):913-7.
11 Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res JT - Recent progress in hormone research, 2004,59:305-31.
12 Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature JT -Nature, 1998, 395 (6704): 763-70.
13 Flier JS. Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 1998, 83 (5): 1407-13.
14 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell JT - Cell, 2004,116(2): 337-50.
15 Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett JT - FEBS letters, 2005, 579(2):295-301.
16 Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature JT - Nature, 1998,394(6696):897-901.
17 Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2002, 26(11): 1407-33.
18 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem JT - The Journal of biological chemistry, 1996, 271(18):10697-703.
19 Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem JT - The Journal of biological chemistry, 1995, 270(45): 26746-9.
20 Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun JT - Biochemical and biophysical research communications, 1996, 221(2):286-9.
21 Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem JT - Journal of biochemistry, 1996,120(4): 803-12.
22 Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care JT - Diabetes care, 2003, 26 (8): 2442-50.
23 Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med JT - Nature medicine, 2002, 8(11): 1288-95.
24 Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature JT -Nature, 2003, 423(6941): 762-9.
25 Yoon MJ, Lee GY, Chung JJ, et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes JT Diabetes, 2006, 55 (9): 2562-70.
26 Ouchi N, Kihara S, AritaY, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation JT Circulation, 2000, 102(11): 1296-301.
27 Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes JT -Diabetes, 2007, 56(5): 1387-94.
28 Dietze-Schroeder D, Sell H, Uhlig M, et al. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes JT - Diabetes, 2005, 54(7): 2003-11.
29 Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia JT - Diabetologia, 2003,46(4):459-69.
30 Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2001,86(5):1930-5.
31 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes JT - Diabetes, 2001, 50(5): 1126-33.
32 Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(4):1907-10.
33 Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2003,148(3):293-300.
34 Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology JT -Endocrinology, 2004,145(2): 484-6.
35 Weiss R, Dufour S, Groszmann A, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003,88(5):2014-8.
36 Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem JT - The Journal of biological chemistry, 2002,277 (29): 25863-6.
37 Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med JT - Nature medicine, 2002, 8(7):731-7.
38 Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology JT -Endocrinology, 2004,145(1): 367-83.
39 Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008.
40 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation JT - Circulation, 1999,100(25): 2473-6.
41 Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev JT - Cytokine & growth factor reviews, 2003,14 (5): 447-55.
42 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science JT - Science (New York, N.Y.), 1993, 259(5091): 87-91.
43 Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature JT - Nature, 1997,389(6651):610-4.
44 Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003,27 Suppl 3:S53-5.
45 Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes JT -Diabetes, 2002, 51(11) :3176-88.
46 Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology, 2005, 25(10): 2062-8.
47 Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signal ing-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem JT -The Journal of biological chemistry, 2003, 278(16):13740-6.
48 Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med JT - Nature medicine, 2002, 8(1):75-9.
49 De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest JT - The Journal of clinical investigation, 1997, 99(4):643-50.
50 Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest JT - The Journal of clinical investigation, 2003, 112(12):1785-8.
51 Zhou HR, Kim EK, Kim H, et al. Obesity-associated mouse adipose stem cell secretion of monocyte chemotactic protein-1. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2007, 293(5):El153-8.
52 Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem JT - The Journal of biological chemistry, 2003, 278(47) :46654-60.
53 Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest JT - The Journal of clinical investigation, 2003,112(12):1821-30.
54 Gerhardt CC, Romero IA, Cancello R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol JT - Molecular and cellular endocrinology, 2001, 175(1-2) :81-92.
55 Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem JT - The Journal of biological chemistry, 2006, 281(36):26602-14.
56 Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(12):7265-70.
57 Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol JT - The international journal of biochemistry & cell biology, 2003, 35(6):807-25.
58 Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev JT - Obesity reviews : an official journal of the International Association for the Study of Obesity, 2003, 4(1) :43-55.
59 Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J JT - The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, 15(14) :2727-9.
60 Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology JT -Endocrinology, 2001,142(12):5220-5.
61 Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest JT - The Journal of clinical investigation, 2003,112(1):83-90.
62 Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost JT - Journal of thrombosis and haemostasis : JTH, 2003,1 (7): 1575-9.
63 Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes JT - Diabetes, 2004,53(2):336-46.
64 Schafer K, Fujisawa K, Konstantinides S, et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J JT - The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001,15(10): 1840-2.
65 Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev JT -Obesity reviews : an official journal of the International Association for the Study of Obesity, 2002, 3(2) :85-101.
66 Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest JT - The Journal of clinical investigation, 2000, 105(3) :271-8.
67 Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28 Suppl 4-.S12-21.
68 Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes JT -Diabetes, 2007,56(4):901-11.
69 Weyer C, Foley JE, Bogardus C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia JT -Diabetologia, 2000, 43(12): 1498-506.
70 Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2001, 49(1):119-26.
71 Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest JT - The Journal of clinical investigation, 1989, 83(4): 1168-73.
72 Arner P, Hellstrom L, Wahrenberg H, et al. Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest JT - The Journal of clinical investigation, 1990, 86 (5): 1595-600.
73 Hellmer J, Marcus C, Sonnenfeld T, et al. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 1992,75(1):15-20.
74 Bjorntorp P. [Metabolic difference between visceral fat and subcutaneous abdominal fat]. Diabetes Metab JT - Diabetes & metabolism, 2000,26 Suppl 3:10-2.
75 Van Harmelen V, Lonnqvist F, Thorne A, et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997,21(11):972-9.
76 van Harmelen V, Dicker A, Ryden M, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes JT - Diabetes, 2002,51(7): 2029-36.
77 Ross R, Aru J, Freeman J, et al. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2002,282(3) :E657-63.
78 Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. Diabetes JT - Diabetes, 2002,51 (4): 1005-15.
79 Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes JT - Diabetes, 2002, 51(10): 2951-8.
80 Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest JT - The Journal of clinical investigation, 2003,112(12): 1796-808.
81 Bouloumie A, Curat CA, Sengenes C, et al. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care JT - Current opinion in clinical nutrition and metabolic care, 2005, 8(4):347-54.
82 Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev JT - Endocrine reviews, 2006, 27(5):449-67.
83 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev JT - Endocrine reviews, 1999, 20(5):649-88.
84 Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest JT - The Journal of clinical investigation, 1997, 99(10) :2416-22.
85 Prusty D, Park BH, Davis KE, et al. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem JT - The Journal of biological chemistry, 2002, 277(48):46226-32.
86 Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med JT - Nature medicine, 2004, 10(4) :355-61.
87 Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A JT -Proceedings of the National Academy of Sciences of the United States of America, 1998,95(13) :7614-9.
88 Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev JT - Genes & development, 2002,16(1): 22-6.
89 Fajas L, Schoonjans K, Gelman L, et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol JT - Molecular and cellular biology, 1999, 19(8):5495-503.
90 Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell JT - Cell, 1995,83(5):803-12.
91 Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem JT - The Journal of biological chemistry, 1995, 270(22):12953-6.
92 Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest JT -The Journal of clinical investigation, 1998,101(6):1354-61.
93 Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest JT - The Journal of clinical investigation, 1997,100(12):3149-53.
94 Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell JT - Molecular cell, 1999,4(4):611-7.
95 Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care JT - Diabetes care, 2004,27(7): 1660-7.
96 He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2003,100 (26): 15712-7.
97 Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2005,102(17) :6207-12.
98 Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest JT - The Journal of clinical investigation, 2000,106(10): 1221-8.
99 de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes JT - Diabetes, 2001, 50(8): 1863-71.
100 Norris AW, Chen L, Fisher SJ, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest JT - The Journal of clinical investigation, 2003, 112(4):608-18.
101 Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2002,87(6):2784-91.
102 Bajaj M, Suraamornkul S, Hardies LJ, et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28(6):783-9.
103 Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes JT - Diabetes, 2004,53(8): 2169-76.
104 Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism JT - Metabolism: clinical and experimental, 2005,54(1):24-32.
105 Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2005, 288(5) :E930-4.
106 Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab JT - Diabetes, obesity & metabolism, 2004, 6(2): 133-56.
107 Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004, 89(9):4312-9.
108 Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev JT - Endocrine reviews, 2002, 23(2): 201-29.
109 Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004,89(1):200-6.
110 Yki-Jarvinen H. Thiazolidinediones. N Engl J Med JT - The New England journal of medicine, 2004, 351 (11): 1106-18.
111 Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care JT - Diabetes care, 2005, 28(7): 1547-54.
112 Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care JT - Diabetes care, 2007,30(10):2458-64.
113 Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes JT - Diabetes, 2001, 50(9): 2094-9.
114 Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?. Int J Obes (Lond) JT - International journal of obesity (2005), 2005,29 Suppl 1:S17-23.
115 Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem JT - The Journal of biological chemistry, 2006,281 (13):8748-55.
116 Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem JT - The Journal of biological chemistry, 2004, 279(13):12152-62.
117 Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem JT - The Journal of biological chemistry, 2006, 281(5): 2654-60.
118 Kanatani Y, Usui I, Ishizuka K, et al. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes JT -Diabetes, 2007,56(3):795-803.
119 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature JT -Nature, 1998, 391(6662): 82-6.
120 Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature JT -Nature, 1998, 391(6662): 79-82.
121 Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1994,91(23):10878-82.
122 Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(9):4637-41.
123 Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem JT -The Journal of biological chemistry, 1997, 272(48):30261-9.
124 Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2004, 286(4) :E560-7.
125 Lin CY, Gurlo T, Haataja L, et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a Phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2005,90(12): 6678-86.
126 Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes JT - Diabetes, 2001, 50(5) :1021-9.
127 Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care JT - Diabetes care, 2004, 27(11) :2585-9.
128 Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes JT -Diabetes, 2002,51(8):2341-7.
129 Deeb SS, Fajas L, Nemoto M, et al. A Prol2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet JT - Nature genetics, 1998, 20(3):284-7.
130 Swarbrick MM, Chapman CM, McQuillan BM, et al. A Prol2Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2001, 144(3) :277-82.
131 Beamer BA, Yen CJ, Andersen RE, et al. Association of the Prol2Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes JT -Diabetes, 1998,47(11): 1806-8.
132 Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet JT - Journal of medical genetics, 2003, 40 (10) :773-80.
133 Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes JT -Diabetes, 2001, 50(3): 686-9.
134 Robitaille J, Despres JP, Perusse L, et al. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet JT - Clinical genetics, 2003, 63(2):109-16.
135 Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res JT - Journal of lipid research, 2004,45(4):674-85.
136 Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet JT - Annual review of genomics and human genetics, 2003,4:257-91.
137 Doney AS, Fischer B, Cecil JE, et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia JT Diabetologia, 2004, 47 (3): 555-8.
138 Iwata E, Yamamoto I, MotomuraT, et al. The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2003, 62(1):55-9.
139 Yan ZC, Zhu ZM, Shen CY, et al. [Peroxisome proliferator-activated receptor gamma C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome]. Zhonghua Yi Xue Za Zhi JT - Zhonghua yi xue za zhi, 2004, 84(7):543-7.
140 Qi L, Doria A, Manson JE, et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes JT - Diabetes, 2006,55(5): 1512-6.
141 Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care JT - Diabetes care, 2005, 28 (5): 1139-44.
142 Kang ES, Cha BS, Kim HJ, et al. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care JT - Diabetes care, 2006, 29(6): 1320-4.
1 Riddle MC.Evening insulin strategy.Diabetes Care JT-Diabetes care,1990,13(6):676-86.
2 Global Guideline for Type 2 Diabetes:recommendations for standard,comprehensive,and minimal care.Diabet Med JT-Diabetic medicine:a journal of the British Diabetic Association,2006,23(6):579-93.
3 Heinemann L,Linkeschoya R,Rave K,et al.Time-action profile of the long-acting insulin analog insulin glargine(HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care JT-Diabetes care,2000,23(5):644-9.
4 Becker RH,Frick AD,Teichert L,et al.Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.Diabetes Obes Metab JT-Diabetes,obesity &metabolism,2008.
5 Dailey G,Strange P.Lower severe hypoglycemia risk:insulin glargine versus NPH insulin in type 2 diabetes.Am J Manag Care JT-The American journal of managed care,2008,14(1):25-30.
6 Pan CY,Sinnassamy P,Chung KD,et al.Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.Diabetes Res Clin Pract JT-Diabetes research and clinical practice,2007,76(1):111-8.
7 Yeap BB.Type 2 diabetes mellitus-guidelines for initiating insulin therapy.Aust Fam Physician JT-Australian family physician,2007,36(7):549-53.
8 Riddle MC,Rosenstock J,Gerich J.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26(11): 3080-6.
9 Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U. S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care JT - Diabetes care, 2004,27(1): 17-20.
10 Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005,28(2):260-5.
11 Tahrani AA, Digwood S, Lee C, et al. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract JT - International journal of clinical practice, 2007, 61(2):329-35.
12 Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006,63(24) :2473-82.
13 Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc JT - Journal of the American Geriatrics Society, 2007,55(2):182-8.
14 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care JT - Diabetes care, 2005,28(4):950-5.
15 Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care JT - Diabetes care, 2005, 28(2):254-9.
16 Schiel R, Muller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008,116(1): 58-64.
17 Davies M, Sinnassamy P, Storms F, et al. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2008, 79(2): 368-75.
1 Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacyof addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care JT -Diabetes care, 2002, 25(2): 330-6.
2 Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev JT Diabetes/metabolism research and reviews, 2000,16(3): 179-91.
3 Simon C, Brandenberger G. Ultradian oscillations of insulin secretion in humans. Diabetes JT - Diabetes, 2002,51 Suppl 1:S258-61.
4 Lefebvre PJ, Paolisso G, Scheen AJ, et al. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia JT -Diabetologia, 1987, 30(7): 443-52.
5 贾伟平,项坤三. 胰岛B细胞功能评估——从基础到临床. 中华内分泌代谢杂志, 2005,21:199-201.
6 Weir GC, Laybutt DR, Kaneto H, et al. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes JT -Diabetes, 2001,50 Suppl l:S154-9.
7 Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes JT - Diabetes, 2003,52(1): 102-10.
8 Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003,88(5): 2300-8.
9 Chen C, Hosokawa H, Bumbalo LM, et al. Regulatory effects of glucose on the catalytic activity and cellular content of glucokinase in the pancreatic beta cell. Study using cultured rat islets. J Clin Invest JT -The Journal of clinical investigation, 1994,94(4) : 1616-20.
10 Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes JT - Diabetes, 1991,40(2): 166-80.
11 Lingvay I, Kaloyanova PF, Adams-Huet B, et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2007, 55(2):62-8.
12 Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med JT - The New England journal of medicine, 1997, 337 (3): 176-83.
13 Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes JT -Diabetes, 1997, 46(3): 440-3.
14 Ashwell SG, Bradley C, Stephens JW, et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetes Care JT - Diabetes care, 2008.
15 Porcellati F, Rossetti P, Bolli GB, et al. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study: Response to Banarer. Diabetes Care JT - Diabetes care, 2008,31(3):e17.
16 Becker RH, Frick AD, Teichert L, et al. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Diabetes Obes Metab JT - Diabetes, obesity & metabolism, 2008.
17 Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin JT - Current medical research and opinion, 2004, 20(1):31—7.
18 Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 1999,16 (4): 332-8.
19 Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia JT - Diabetologia, 1996,39(3):281-8.
20 Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding and time action of acylated insulins in various species. J Pharra Sci JT - Journal of pharmaceutical sciences, 1996,85(3):304-8.
21 Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care JT - Diabetes care, 2005, 28(5): 1107-12.
22 Porcellati F, Rossetti P, Ricci Busciantella N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care, 2007.
23 Kiess W, Raile K, Galler A, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care JT - Diabetes care, 2004, 27(10):2567-8.
24 Heise T, Nosek L, Ronn BB, et ak Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes JT - Diabetes, 2004, 53(6):1614-20.
25 Russell-Jones D. Insulin detemir: improving the predictability of glycaemic control. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28 Suppl 2:S29-34.
26 Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2005, 7(1): 56-64.
27 Dornhorst A, Luddeke HJ, Honka M, et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin JT - Current medical research and opinion, 2008, 24(2):369-76.
28 Rosenstock J, Davies M, Home PD, et al. Arandomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia JT -Diabetologia, 2008, 51(3) :408-16.
29 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003, 26(11):3080-6.
30 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005,28(4): 950-5.
31 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care JT -Diabetes care, 2005, 28(4): 950-5.
32 Hamann A, Matthaei S, Rosak C, et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care JT - Diabetes care, 2003, 26(6): 1738-44.
33 Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol JT - European journal of clinical pharmacology, 2000, 56(5): 399-403.
34 Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care JT - Diabetes care, 1999,22(8): 1258-61.
35 Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006,114(9) :511-9.
36 Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2006,8(1):58-66.
37 Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associatedwith lispro insulin in insulin pump therapy: an old complication, a new cause?. Diabetes Care JT - Diabetes care, 2001,24(1): 174.
38 Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy, is there any insulin preparation free of complications?. Diabetes Care JT - Diabetes care, 2003, 26(3) :953-4.
39 Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Diabetes Care JT - Diabetes care, 2005,28(12):2983.
40 Del Olmo MI, Campos V, Abellan P, et al. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2008.
41 Masson EA, Patmore JE, Brash PD, et al. Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2003,20(1):46-50.
42 . Scherbaum WA, Lankisch MR, Pawlowski B, et al. Insulin Lispro in pregnancy—retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2002,110(1) :6-9.
43 Boskovic R, Feig DS, Derewlany L, et al. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care JT - Diabetes care, 2003, 26(5):1390-4.
44 Bhattacharyya A, Brown S, Hughes S, et al. Insulin lispro and regular insulin in pregnancy. QJM JT - QJM : monthly journal of the Association of Physicians, 2001, 94(5):255-60.
45 Kitzmiller JL. Insulin lispro and the development of Proliferative diabetic retinopathy during pregnancy. Am J Obstet Gynecol JT - American journal of obstetrics and gynecology, 2001, 185(3):774-5.
46 Buchbinder A, Miodovnik M, McElvy S, et al. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?. Am J Obstet Gynecol JT - American journal of obstetrics and gynecology, 2000,183(5): 1162-5.
47 Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med JT - Annals of internal medicine, 2005,143(8):549-58.
48 Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care JT - Diabetes care, 2007, 30(4): 771-6.
49 Gallen IW, Jaap A, Roland JM, et al. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2008, 25(2):165-9.
50 Rachmiel M, Perlman K, Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am JT - Pediatric clinics of North America, 2005, 52(6):1651-75.
51 Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)—I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet JT - Lancet, 2004, 363(9418):1346-53.
52 Le Roith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev JT - Diabetes/metabolism research and reviews, 2007, 23(8):593-9.
53 Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care JT - Diabetes care, 2006, 29(3):554-9.
54 Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005, 28(2):254-9.
55 Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005,28(2):260-5.
56 Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med JT - Annals of internal medicine, 2005,143 (8): 559-69.
57 Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther JT -Clinical therapeutics, 2007,29(11): 2333-48.
58 Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol JT - Acta diabetologica, 2008, 45(1):53-9.
59 Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther JT - Clinical therapeutics, 2007, 29(11):2349-64.
60 Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin, 2008.
61 Schreiber SA, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther JT - Diabetes technology & therapeutics, 2008,10(2): 121-7.
62 Kawamori R, Eliaschewitz FG, Takayama H, et al. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract JT -Diabetes research and clinical practice, 2008, 79(1):97-102.
63 Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care JT - Diabetes care, 2001,24 (7): 1226-32.
64 Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther JT - Clinical therapeutics, 2007,29 Spec No:1236-53.
65 Janka HU, Hessel F, Walzer S, et al. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). Int J Clin Pharmacol Ther JT - International journal of clinical pharmacology and therapeutics, 2007,45(12): 623-30.
66 Simons WR, Vinod HD, Gerber RA, et al. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006,114(9): 520-6.
67 Zheng L, Buchanan TA, Hodis HN, et al. Time from diagnosis of type 2 diabetes to initiation of insulin therapy is related to carotid artery intima-media thickness. Atherosclerosis JT - Atherosclerosis, 2003,170(2): 293-9.
68 Bogdanski P, Pupek-Musialik D, Dytfeld J, et al. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther JT - International journal of clinical pharmacology and therapeutics, 2007, 45(10):563-7.
69 Origin Trial Investigators, Gerstein H, Yusuf S, et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J JT - American heart journal, 2008,155(1):26-32, 32. e1-6.
70 Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care JT - Diabetes care, 2004, 27(10): 2356-62.
71 Cefalu WT. Inhaled insulin: a proof-of-concept study. Ann Intern Med JT - Annals of internal medicine, 2001,134(9 Pt 1):795.
72 Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med JT - Annals of internal medicine, 2001,134(3):203-7.
73 Skyler JS, Jovanovic L, Klioze S, et, al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care JT - Diabetes care, 2007,30(3):579-85.
74 Barnett AH, Lange P, Dreyer M, et al. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract JT - International journal of clinical practice, 2007,61 (10): 1614-25.
75 Liu MC, Riese RJ, Van Gundy K, et al. Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. Eur Respir J JT - The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 2008.
76 Keegan A. Exit Exubera. Inhalable insulin is withdrawn due to weak sales. Diabetes Forecast JT - Diabetes forecast, 2007,60(13): 19.
77 Black C, Cummins E, Royle P, et al. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess JT - Health technology assessment (Winchester, England), 2007,11(33):1-126.
2 Miles JM,Nelson RH.Contribution of triglyceride-rich lipoproteins to plasma free fatty acids.Horm Metab Res JT-Hormoneand metabolic research.Hormon-und Stoffwechselforschung.Hormones et metabolisme,2007,39(10):726-9.
3 Mostaza JM,Vega GL,Snell P,et al.Abnormal metabolism of free fatty acids in hypertriglyceridaemic men:apparent insulin resistance of adipose tissue.J Intern Med JT -Journal of internal medicine,1998,243(4):265-74.
4 Siiteri PK.Adipose tissue as a source of hormones.Am J Clin Nutr JT-The American journal of clinical nutrition,1987,45(1 Suppl):277-82.
5 Fruhbeck G,Gomez-Ambrosi J,Muruzabal FJ,et al.The adipocyte:a model for integration of endocrine and metabolic signaling in energy metabolism regulation.Am J Physiol Endocrinol Metab JT-American journal of physiology.Endocrinology and metabolism,2001,280(6):E827-47.
6 Dobbins RL,Chester,,Daniels MB,et al.Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans.Diabetes JT-Diabetes,1998,47(10):1613-8.
7 Boden G,Chen X,Iqbal N.Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.Diabetes JT-Diabetes,1998,47(10):1609-12.
8 Trayhurn P,Wood IS.Adipokines:inflammation and the pleiotropic role of white adipose tissue.Br J Nutr JT-The British journal of nutrition,2004,92(3):347-55.
9 Paolisso G,Tataranni PA,Foley JE,et al.A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.Diabetologia JT -Diabetologia,1995,38(10):1213-7.
10 Chen X,Iqbal N,Boden G.The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects.J Clin Invest JT-The Journal of clinical investigation,1999,103(3):365-72.
11 Eorpeleijn E,Mensink M,Kooi ME,et al.Impaired Skeletal Muscle Substrate Oxidation in Glucose-intolerant Men Improves After Weight Loss.Obesity(Silver Spring) JT-Obesity (Silver Spring,Md.),2008.
12 Jensen MD,Haymond MW,Rizza RA,et al.Influence of body fat distribution on free fatty acid metabolism in obesity.J Clin Invest JT-The Journal of clinical investigation,1989,83(4):1168-73.
13 杨文英,邢小燕,林红等.高甘油三酯血症是非胰岛素依赖型糖尿病发病的危险因素-432例非糖尿病人群六年前瞻性观察.中华内科杂志,1995,34:583-586.
14 Grundy SM.Obesity,metabolic syndrome,and cardiovascular disease.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2004,89(6):2595-600.
15 Wajchenberg BL.Subcutaneous and visceral adipose tissue:their relation to the metabolic syndrome.Endocr Rev JT-Endocrine reviews,2000,21(6):697-738.
16 Hallakou S,Ooare L,Foufelle F,et al.Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.Diabetes JT-Diabetes,1997,46(9):1393-9.
17 Wang B,Li HL,Yang WY.Effect of lipid infusion on the function of islet β cells and gene expression of insulin signal transduction system.Beijing Da Xue Xue Bao,2007,39(5):462-466.
18 卜石,杨文英,王昕等.长期高脂饲养对大鼠葡萄糖刺激的胰岛素分泌的影响.中华内分泌代谢杂志,2003,19(1):25-28.
19 白秀平,李宏亮,杨文英等.脂肪分存的顺序及其与胰岛素抵抗的关系.中华内分泌代谢杂志,2007,23(4):307-310.
20 赵文惠,萧建中,杨文英等.高脂饲养及罗格列酮干预对大鼠胰岛素信号系统基因表达的影响.中国糖尿病杂志,2007,15(3):180-183.
21 陈晓平,杨文英,萧建中等.马来酸罗格列酮干预高脂饲养大鼠脂肪肝的研究.中国糖尿病杂志,2006,14(5):380-382.
22 Koh EH,Kim MS,Park JY,et al.Peroxisome proliferator-activated receptor(PPAR)-alpha activation prevents diabetes in OLETF rats:comparison with PPAR-gamma activation.Diabetes JT-Diabetes,2003,52(9):2331-7.
23 Phillips DI,Clark PM,Hales CN,et al.Understanding oral glucose tolerance:comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.Diabet Med JT-Diabetic medicine:a journal of the British Diabetic Association,1994,11(3):286-92.
24 Alberti KG,Zimmet P,Shaw J.The metabolic syndrome-a new worldwide definition.Lancet JT-Lancet,2005,366(9491):1059-62.
25 Fernandez-Real JM,Lopez-Bermejo A,Casamitjana R,et al.Novel interactions of adiponectin with the endocrine system and inflammatory parameters.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2003,88(6):2714-8.
26 Gerstein HC,Yusuf S,Bosch J,et al.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:a randomised controlled trial.Lancet JT-Lancet,2006,368(9541):1096-105.
27 Mayerson AB,Hundal RS,Dufour S,et al.The effects of rosiglitazone on insulin sensitivity,lipolysis,and hepatic and skeletal muscle triglyceride content in patients with type 2diabetes.Diabetes JT-Diabetes,2002,51(3):797-802.
28 Miyazaki Y,Mahankali A,Matsuda M,et al.Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2002,87(6):2784-91.
29 de Souza CJ,Eckhardt M,Gagen K,et al.Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance.Diabetes JT-Diabetes,2001,50(8):1863-71.
30 Miyazaki Y,Mahankali A,Wajcberg E,et al.Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2004,89(9):4312-9.
31 Serlie MJ,Allick G,Groener JE,et al.Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type Ⅱ from free fatty acid-induced insulin resistance.J Clin Endocrinol Metab JT-The Journal of clinical endocrinology and metabolism,2007,92(1):166-71.
32 Mori Y,Murakawa Y,Okada K,et al.Effect of troglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care JT-Diabetes care,1999,22(6):908-12.
33 Laplante M,Festuccia WT,Soucy G,et al.Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.Diabetes JT- Diabetes, 2006,55(10): 2771-8.
34 Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care JT - Diabetes care, 2004,27(7): 1660-7.
35 Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism JT - Metabolism: clinical and experimental, 2005,54(1):24-32.
36 Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care JT - Diabetes care, 2003,26(11) :3148-52.
37 Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2005,288(5) :E930-4.
38 Dietze-Schroeder D, Sell H, Uhlig M, et al. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes JT - Diabetes, 2005,54(7): 2003-11.
39 Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2001,98(4):2005-10.
40 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation JT - Circulation, 1999,100(25): 2473-6.
41 Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes JT -Diabetes, 2007, 56(5): 1387-94.
42 Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation JT -Circulation, 2000, 102(11): 1296-301.
43 Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes JT - Diabetes, 2002,51 (6): 1884-8.
44 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes JT - Diabetes, 2001,50(5): 1126-33.
45 Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(4):1907-10.
46 Chandran M, Phillips SA, Ciaraldi T. et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care JT - Diabetes care, 2003, 26(8): 2442-50.
47 Weiss R, Dufour S, Groszmann A, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(5):2014-8.
48 Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes JT - Diabetes, 2003,52(7): 1655-63.
49 Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest JT -The Journal of clinical investigation, 1998,101(6):1354-61.
50 Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004,89(1):200-6.
51 Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med JT - Nature medicine, 2002,8(11): 1288-95.
52 Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest JT - The Journal of clinical investigation, 1997,100(7): 1863-9.
53 Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008.
54 Koenig W, Khuseyinova N, Baumert J, et al. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol JT - Journal of the American College of Cardiology, 2006, 48(7):1369-77.
55 Maegawa H, Nishio Y, Nakao K, et al. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. Endocr J JT - Endocrine journal, 2007,54(4) :613-8.
56 Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology, 2005,25(10): 2062-8.
57 Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator—activated receptor-gamma. Diabetes JT - Diabetes, 2001,50(5): 1083-92.
58 Martens FM, Rabelink TJ, op't Roodt J, et al. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J JT - European heart journal, 2006, 27(13): 1605-9.
59 Shimizu H, Oh-I S, Tsuchiya T, et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2006, 23(3): 253-7.
60 Shibasaki M, Takahashi K, Itou T, et al. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun JT - Biochemical and biophysical research communications, 2003, 309(2):419-24.
61 Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes JT -Diabetes, 2005,54(8): 2305-13.
62 Cerasi E, Luft R, Efendic S. Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes JT -Diabetes, 1972, 21 (4): 224-34.
63 O'Rahilly SP, Nugent Z, Rudenski AS, et al. Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet JT - Lancet, 1986, 2(8503): 360-4.
64 Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA JT - JAMA : the journal of the American Medical Association, 1995, 273(23): 1855-61.
65 Yoneda H, Ikegami H, Yamamoto Y, et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care JT - Diabetes care, 1992, 15(11): 1517-21.
66 Pimenta W, Mitrakou A, Jensen T, et al. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 1996,13(9 Suppl 6):S33-6.
67 Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care JT - Diabetes care, 1997, 20(10): 1562-8.
68 Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1994,91(23):10878-82.
69 Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1997,94(9):4637-41.
70 Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and Somatostatin levels. J Biol Chem JT -The Journal of biological chemistry, 1997, 272(48):30261-9.
71 Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes JT - Diabetes, 2001,50(5): 1021-9.
72 Matsui J, Terauchi Y, Kubota N, et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes JT -Diabetes, 2004, 53(11):2844-54.
73 Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology JT -Endocrinology, 2001,142(3): 1269-77.
74 Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2004, 286(4):E560-7.
75 Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care JT - Diabetes care, 2004,27(11) :2585-9.
76 Racette SB, Davis AO, McGill JB, et al. Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus. Metabolism JT - Metabolism: clinical and experimental, 2002, 51(2): 169-74.
77 Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia JT - Diabetologia, 2001,44(12):2210-9.
78 Furtner M, Kiechl S, Mair A, et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J JT - European heart journal, 2005, 26(3):279-87.
79 Stehouwer CD, Nauta JJ, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet JT -Lancet, 1992, 340(8815): 319-23.
80 Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia JT -Diabetologia, 1989, 32(4): 219-26.
81 Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation JT - Circulation, 2002,106(14): 1777-82.
82 Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care JT - Diabetes care, 2006, 29 (3): 595-600.
83 Duman D, Demirtunc R, Karadag B, et al. Association of albuminuria with impaired aortic elasticity and left ventricular diastolic dysfunction in type 2 diabetes. Anadolu Kardiyol Derg JT - Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2008,8(1): 10-5.
84 Sung KC, Kim BJ, Ryu S. An association of a variety of cardiovascular risk factors with low grade albuminuria in Korean men. Atherosclerosis JT - Atherosclerosis, 2008,196(1) :320-6.
85 Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med JT - Archives of internal medicine, 1997,157(13):1413-8.
86 Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation JT -Circulation, 2005, 112(7):969-75.
87 Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation JT - Circulation, 2004,110(1):32-5.
88 Ibsen H, Wachtell K, Olsen MH, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens JT - Journal of hypertension, 2004,22(9):1805-11.
89 Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension JT - Hypertension, 2005,45(2):198-202.
90 Lu B, Wen J, Song XY, et al. High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract JT -Diabetes research and clinical practice, 2007,75(2):184-92.
91 Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes JT - Diabetes, 2002, 51 (4): 1157-65.
92 Kshirsagar AV, Bomback AS, Bang H, et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol JT - The American journal of cardiology, 2008,101(3):401-6.
93 Perticone F, Maio R, Tripepi G, et al. Microalbuminuria, endothelial dysfunction and inflammation in primary hypertension. J Nephrol JT - Journal of nephrology, 2007, 20 Suppl 12:S56-62.
94 Ferroni P, Guagnano MT, Falco A, et al. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond) JT -Clinical science (London, England : 1979), 2008,114(6):449-55.
95 Festa A, D'Agostino R, Howard G, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int JT - Kidney international, 2000, 58(4): 1703-10.
96 Nakamura M, Onoda T, Itai K, et al. Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Intern Med JT - Internal medicine (Tokyo, Japan), 2004, 43(10):919-25.
97 Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA JT - JAMA : the journal of the American Medical Association, 2001, 286(4):421-6.
98 Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care JT - Diabetes care, 2006, 29(5): 1039-45.
99 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med JT - The New England journal of medicine, 2002, 346(6):393-403.
100 Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med JT - The New England journal of medicine, 2001, 344(18):1343-50.
101 Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes JT -Diabetes, 2002, 51 (9): 2796-803.
102 Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes JT - Diabetes, 2005,54(4): 1150-6.
103 Moore GB, Pickavance LC, Briscoe CP, et al. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression. Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2008,10(3):251-63.
104 Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2007, 76(2):279-89.
105 Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes JT - Diabetes, 2005, 54(8):2404-14.
106 Kim ES, Im JA, Kim KC, et al. Improved insulin sensitivity and adiponectin level after exercise training in obese Korean youth. Obesity (Silver Spring) JT - Obesity (Silver Spring, Md.), 2007,15(12): 3023-30.
107 Bluher M, Bullen JW Jr, Lee JH, et al. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2006,91(6):2310-6.
108 Bluher M, Williams CJ, Kloting N, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care JT - Diabetes care, 2007, 30(12) :3110-5.
109 Rasmussen MS, Lihn AS, Pedersen SB, et al. Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) JT -Obesity (Silver Spring, Md.), 2006, 14(1) :28-35.
110 Hulver MW, Zheng D, Tanner CJ, et al. Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2002, 283(4) :E861-5.
111 Ryan AS, Berman DM, Nicklas BJ, et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care JT - Diabetes care, 2003, 26(8):2383-8.
112 Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004, 89 (6): 2697-703.
113 Arai K, Soga T, Ohata H, et al. Effects of food restriction on peroxisome proliferator-activated receptor-gamma and glucocorticoid receptor signaling in adipose tissues of normal rats. Metabolism JT - Metabolism: clinical and experimental, 2004,53(1) :28-36.
114 Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2001, 86(8):3815-9.
115 Madsen EL, Rissanen A, Bruun JM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2008,158(2):179-87.
116 The Diabetes Prevention Program.Design and methods for a clinical trial in the prevention of type 2 diabetes.Diabetes Care JT-Diabetes care,1999,22(4):623-34.
1 Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets JT - Current drug targets, 2004, 5(3):241-50.
2 Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr JT - The American journal of clinical nutrition, 1987,45(1 Suppl):277-82.
3 Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature JT -Nature, 1994,372(6505): 425-32.
4 Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2001, 280 (6): E827-47.
5 Frayn KN, Karpe F, Fielding BA, et al. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003, 27 (8): 875-88.
6 Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest JT - Journal of endocrinological investigation, 2002, 25(10):823-35.
7 Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature JT -Nature, 2001, 409(6818): 307-12.
8 Bruun JM, Stallknecht B, Helge JW, et al. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2007,157(4):465-71.
9 Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology JT -Endocrinology, 2004,145(5):2273-82.
10 Van Harmelen V, Reynisdottir S, Eriksson P, et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes JT - Diabetes, 1998,47(6):913-7.
11 Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res JT - Recent progress in hormone research, 2004,59:305-31.
12 Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature JT -Nature, 1998, 395 (6704): 763-70.
13 Flier JS. Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 1998, 83 (5): 1407-13.
14 Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell JT - Cell, 2004,116(2): 337-50.
15 Otero M, Lago R, Lago F, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett JT - FEBS letters, 2005, 579(2):295-301.
16 Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature JT - Nature, 1998,394(6696):897-901.
17 Margetic S, Gazzola C, Pegg GG, et al. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2002, 26(11): 1407-33.
18 Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem JT - The Journal of biological chemistry, 1996, 271(18):10697-703.
19 Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem JT - The Journal of biological chemistry, 1995, 270(45): 26746-9.
20 Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun JT - Biochemical and biophysical research communications, 1996, 221(2):286-9.
21 Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem JT - Journal of biochemistry, 1996,120(4): 803-12.
22 Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care JT - Diabetes care, 2003, 26 (8): 2442-50.
23 Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med JT - Nature medicine, 2002, 8(11): 1288-95.
24 Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature JT -Nature, 2003, 423(6941): 762-9.
25 Yoon MJ, Lee GY, Chung JJ, et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes JT Diabetes, 2006, 55 (9): 2562-70.
26 Ouchi N, Kihara S, AritaY, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation JT Circulation, 2000, 102(11): 1296-301.
27 Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes JT -Diabetes, 2007, 56(5): 1387-94.
28 Dietze-Schroeder D, Sell H, Uhlig M, et al. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes JT - Diabetes, 2005, 54(7): 2003-11.
29 Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia JT - Diabetologia, 2003,46(4):459-69.
30 Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2001,86(5):1930-5.
31 Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes JT - Diabetes, 2001, 50(5): 1126-33.
32 Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003, 88(4):1907-10.
33 Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2003,148(3):293-300.
34 Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. Endocrinology JT -Endocrinology, 2004,145(2): 484-6.
35 Weiss R, Dufour S, Groszmann A, et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003,88(5):2014-8.
36 Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem JT - The Journal of biological chemistry, 2002,277 (29): 25863-6.
37 Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med JT - Nature medicine, 2002, 8(7):731-7.
38 Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology JT -Endocrinology, 2004,145(1): 367-83.
39 Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008.
40 Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation JT - Circulation, 1999,100(25): 2473-6.
41 Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev JT - Cytokine & growth factor reviews, 2003,14 (5): 447-55.
42 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science JT - Science (New York, N.Y.), 1993, 259(5091): 87-91.
43 Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature JT - Nature, 1997,389(6651):610-4.
44 Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003,27 Suppl 3:S53-5.
45 Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes JT -Diabetes, 2002, 51(11) :3176-88.
46 Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol JT - Arteriosclerosis, thrombosis, and vascular biology, 2005, 25(10): 2062-8.
47 Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signal ing-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem JT -The Journal of biological chemistry, 2003, 278(16):13740-6.
48 Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med JT - Nature medicine, 2002, 8(1):75-9.
49 De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest JT - The Journal of clinical investigation, 1997, 99(4):643-50.
50 Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest JT - The Journal of clinical investigation, 2003, 112(12):1785-8.
51 Zhou HR, Kim EK, Kim H, et al. Obesity-associated mouse adipose stem cell secretion of monocyte chemotactic protein-1. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2007, 293(5):El153-8.
52 Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem JT - The Journal of biological chemistry, 2003, 278(47) :46654-60.
53 Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest JT - The Journal of clinical investigation, 2003,112(12):1821-30.
54 Gerhardt CC, Romero IA, Cancello R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol JT - Molecular and cellular endocrinology, 2001, 175(1-2) :81-92.
55 Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem JT - The Journal of biological chemistry, 2006, 281(36):26602-14.
56 Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(12):7265-70.
57 Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol JT - The international journal of biochemistry & cell biology, 2003, 35(6):807-25.
58 Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev JT - Obesity reviews : an official journal of the International Association for the Study of Obesity, 2003, 4(1) :43-55.
59 Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J JT - The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, 15(14) :2727-9.
60 Massiera F, Seydoux J, Geloen A, et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology JT -Endocrinology, 2001,142(12):5220-5.
61 Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest JT - The Journal of clinical investigation, 2003,112(1):83-90.
62 Juhan-Vague I, Alessi MC, Mavri A, et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost JT - Journal of thrombosis and haemostasis : JTH, 2003,1 (7): 1575-9.
63 Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes JT - Diabetes, 2004,53(2):336-46.
64 Schafer K, Fujisawa K, Konstantinides S, et al. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J JT - The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001,15(10): 1840-2.
65 Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev JT -Obesity reviews : an official journal of the International Association for the Study of Obesity, 2002, 3(2) :85-101.
66 Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest JT - The Journal of clinical investigation, 2000, 105(3) :271-8.
67 Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28 Suppl 4-.S12-21.
68 Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes JT -Diabetes, 2007,56(4):901-11.
69 Weyer C, Foley JE, Bogardus C, et al. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia JT -Diabetologia, 2000, 43(12): 1498-506.
70 Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2001, 49(1):119-26.
71 Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest JT - The Journal of clinical investigation, 1989, 83(4): 1168-73.
72 Arner P, Hellstrom L, Wahrenberg H, et al. Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest JT - The Journal of clinical investigation, 1990, 86 (5): 1595-600.
73 Hellmer J, Marcus C, Sonnenfeld T, et al. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 1992,75(1):15-20.
74 Bjorntorp P. [Metabolic difference between visceral fat and subcutaneous abdominal fat]. Diabetes Metab JT - Diabetes & metabolism, 2000,26 Suppl 3:10-2.
75 Van Harmelen V, Lonnqvist F, Thorne A, et al. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997,21(11):972-9.
76 van Harmelen V, Dicker A, Ryden M, et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes JT - Diabetes, 2002,51(7): 2029-36.
77 Ross R, Aru J, Freeman J, et al. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2002,282(3) :E657-63.
78 Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations : distinct metabolic effects of two fat compartments. Diabetes JT - Diabetes, 2002,51 (4): 1005-15.
79 Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes JT - Diabetes, 2002, 51(10): 2951-8.
80 Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest JT - The Journal of clinical investigation, 2003,112(12): 1796-808.
81 Bouloumie A, Curat CA, Sengenes C, et al. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care JT - Current opinion in clinical nutrition and metabolic care, 2005, 8(4):347-54.
82 Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev JT - Endocrine reviews, 2006, 27(5):449-67.
83 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev JT - Endocrine reviews, 1999, 20(5):649-88.
84 Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest JT - The Journal of clinical investigation, 1997, 99(10) :2416-22.
85 Prusty D, Park BH, Davis KE, et al. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem JT - The Journal of biological chemistry, 2002, 277(48):46226-32.
86 Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med JT - Nature medicine, 2004, 10(4) :355-61.
87 Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A JT -Proceedings of the National Academy of Sciences of the United States of America, 1998,95(13) :7614-9.
88 Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev JT - Genes & development, 2002,16(1): 22-6.
89 Fajas L, Schoonjans K, Gelman L, et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol JT - Molecular and cellular biology, 1999, 19(8):5495-503.
90 Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell JT - Cell, 1995,83(5):803-12.
91 Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem JT - The Journal of biological chemistry, 1995, 270(22):12953-6.
92 Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest JT -The Journal of clinical investigation, 1998,101(6):1354-61.
93 Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest JT - The Journal of clinical investigation, 1997,100(12):3149-53.
94 Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell JT - Molecular cell, 1999,4(4):611-7.
95 Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care JT - Diabetes care, 2004,27(7): 1660-7.
96 He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2003,100 (26): 15712-7.
97 Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 2005,102(17) :6207-12.
98 Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest JT - The Journal of clinical investigation, 2000,106(10): 1221-8.
99 de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes JT - Diabetes, 2001, 50(8): 1863-71.
100 Norris AW, Chen L, Fisher SJ, et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest JT - The Journal of clinical investigation, 2003, 112(4):608-18.
101 Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2002,87(6):2784-91.
102 Bajaj M, Suraamornkul S, Hardies LJ, et al. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28(6):783-9.
103 Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes JT - Diabetes, 2004,53(8): 2169-76.
104 Smith SR, De Jonge L, Volaufova J, et al. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism JT - Metabolism: clinical and experimental, 2005,54(1):24-32.
105 Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2005, 288(5) :E930-4.
106 Buse JB, Tan MH, Prince MJ, et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab JT - Diabetes, obesity & metabolism, 2004, 6(2): 133-56.
107 Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004, 89(9):4312-9.
108 Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev JT - Endocrine reviews, 2002, 23(2): 201-29.
109 Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2004,89(1):200-6.
110 Yki-Jarvinen H. Thiazolidinediones. N Engl J Med JT - The New England journal of medicine, 2004, 351 (11): 1106-18.
111 Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care JT - Diabetes care, 2005, 28(7): 1547-54.
112 Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care JT - Diabetes care, 2007,30(10):2458-64.
113 Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes JT - Diabetes, 2001, 50(9): 2094-9.
114 Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?. Int J Obes (Lond) JT - International journal of obesity (2005), 2005,29 Suppl 1:S17-23.
115 Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem JT - The Journal of biological chemistry, 2006,281 (13):8748-55.
116 Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem JT - The Journal of biological chemistry, 2004, 279(13):12152-62.
117 Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem JT - The Journal of biological chemistry, 2006, 281(5): 2654-60.
118 Kanatani Y, Usui I, Ishizuka K, et al. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes JT -Diabetes, 2007,56(3):795-803.
119 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature JT -Nature, 1998, 391(6662): 82-6.
120 Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature JT -Nature, 1998, 391(6662): 79-82.
121 Lee Y, Hirose H, Ohneda M, et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1994,91(23):10878-82.
122 Shimabukuro M, Koyama K, Chen G, et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(9):4637-41.
123 Gremlich S, Bonny C, Waeber G, et al. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem JT -The Journal of biological chemistry, 1997, 272(48):30261-9.
124 Lupi R, Del Guerra S, Marselli L, et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism, 2004, 286(4) :E560-7.
125 Lin CY, Gurlo T, Haataja L, et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a Phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2005,90(12): 6678-86.
126 Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes JT - Diabetes, 2001, 50(5) :1021-9.
127 Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care JT - Diabetes care, 2004, 27(11) :2585-9.
128 Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes JT -Diabetes, 2002,51(8):2341-7.
129 Deeb SS, Fajas L, Nemoto M, et al. A Prol2Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet JT - Nature genetics, 1998, 20(3):284-7.
130 Swarbrick MM, Chapman CM, McQuillan BM, et al. A Prol2Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol JT - European journal of endocrinology / European Federation of Endocrine Societies, 2001, 144(3) :277-82.
131 Beamer BA, Yen CJ, Andersen RE, et al. Association of the Prol2Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes JT -Diabetes, 1998,47(11): 1806-8.
132 Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet JT - Journal of medical genetics, 2003, 40 (10) :773-80.
133 Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes JT -Diabetes, 2001, 50(3): 686-9.
134 Robitaille J, Despres JP, Perusse L, et al. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet JT - Clinical genetics, 2003, 63(2):109-16.
135 Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res JT - Journal of lipid research, 2004,45(4):674-85.
136 Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet JT - Annual review of genomics and human genetics, 2003,4:257-91.
137 Doney AS, Fischer B, Cecil JE, et al. Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia JT Diabetologia, 2004, 47 (3): 555-8.
138 Iwata E, Yamamoto I, MotomuraT, et al. The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2003, 62(1):55-9.
139 Yan ZC, Zhu ZM, Shen CY, et al. [Peroxisome proliferator-activated receptor gamma C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome]. Zhonghua Yi Xue Za Zhi JT - Zhonghua yi xue za zhi, 2004, 84(7):543-7.
140 Qi L, Doria A, Manson JE, et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes JT - Diabetes, 2006,55(5): 1512-6.
141 Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care JT - Diabetes care, 2005, 28 (5): 1139-44.
142 Kang ES, Cha BS, Kim HJ, et al. The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care JT - Diabetes care, 2006, 29(6): 1320-4.
1 Riddle MC.Evening insulin strategy.Diabetes Care JT-Diabetes care,1990,13(6):676-86.
2 Global Guideline for Type 2 Diabetes:recommendations for standard,comprehensive,and minimal care.Diabet Med JT-Diabetic medicine:a journal of the British Diabetic Association,2006,23(6):579-93.
3 Heinemann L,Linkeschoya R,Rave K,et al.Time-action profile of the long-acting insulin analog insulin glargine(HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care JT-Diabetes care,2000,23(5):644-9.
4 Becker RH,Frick AD,Teichert L,et al.Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.Diabetes Obes Metab JT-Diabetes,obesity &metabolism,2008.
5 Dailey G,Strange P.Lower severe hypoglycemia risk:insulin glargine versus NPH insulin in type 2 diabetes.Am J Manag Care JT-The American journal of managed care,2008,14(1):25-30.
6 Pan CY,Sinnassamy P,Chung KD,et al.Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.Diabetes Res Clin Pract JT-Diabetes research and clinical practice,2007,76(1):111-8.
7 Yeap BB.Type 2 diabetes mellitus-guidelines for initiating insulin therapy.Aust Fam Physician JT-Australian family physician,2007,36(7):549-53.
8 Riddle MC,Rosenstock J,Gerich J.The treat-to-target trial:randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003,26(11): 3080-6.
9 Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U. S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care JT - Diabetes care, 2004,27(1): 17-20.
10 Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005,28(2):260-5.
11 Tahrani AA, Digwood S, Lee C, et al. Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service. Int J Clin Pract JT - International journal of clinical practice, 2007, 61(2):329-35.
12 Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm JT - American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006,63(24) :2473-82.
13 Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc JT - Journal of the American Geriatrics Society, 2007,55(2):182-8.
14 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care JT - Diabetes care, 2005,28(4):950-5.
15 Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care JT - Diabetes care, 2005, 28(2):254-9.
16 Schiel R, Muller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008,116(1): 58-64.
17 Davies M, Sinnassamy P, Storms F, et al. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2008, 79(2): 368-75.
1 Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacyof addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care JT -Diabetes care, 2002, 25(2): 330-6.
2 Bergsten P. Pathophysiology of impaired pulsatile insulin release. Diabetes Metab Res Rev JT Diabetes/metabolism research and reviews, 2000,16(3): 179-91.
3 Simon C, Brandenberger G. Ultradian oscillations of insulin secretion in humans. Diabetes JT - Diabetes, 2002,51 Suppl 1:S258-61.
4 Lefebvre PJ, Paolisso G, Scheen AJ, et al. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia JT -Diabetologia, 1987, 30(7): 443-52.
5 贾伟平,项坤三. 胰岛B细胞功能评估——从基础到临床. 中华内分泌代谢杂志, 2005,21:199-201.
6 Weir GC, Laybutt DR, Kaneto H, et al. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes JT -Diabetes, 2001,50 Suppl l:S154-9.
7 Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes JT - Diabetes, 2003,52(1): 102-10.
8 Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism, 2003,88(5): 2300-8.
9 Chen C, Hosokawa H, Bumbalo LM, et al. Regulatory effects of glucose on the catalytic activity and cellular content of glucokinase in the pancreatic beta cell. Study using cultured rat islets. J Clin Invest JT -The Journal of clinical investigation, 1994,94(4) : 1616-20.
10 Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes JT - Diabetes, 1991,40(2): 166-80.
11 Lingvay I, Kaloyanova PF, Adams-Huet B, et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2007, 55(2):62-8.
12 Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med JT - The New England journal of medicine, 1997, 337 (3): 176-83.
13 Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes JT -Diabetes, 1997, 46(3): 440-3.
14 Ashwell SG, Bradley C, Stephens JW, et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetes Care JT - Diabetes care, 2008.
15 Porcellati F, Rossetti P, Bolli GB, et al. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study: Response to Banarer. Diabetes Care JT - Diabetes care, 2008,31(3):e17.
16 Becker RH, Frick AD, Teichert L, et al. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects. Diabetes Obes Metab JT - Diabetes, obesity & metabolism, 2008.
17 Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin JT - Current medical research and opinion, 2004, 20(1):31—7.
18 Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 1999,16 (4): 332-8.
19 Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia JT - Diabetologia, 1996,39(3):281-8.
20 Kurtzhals P, Havelund S, Jonassen I, et al. Albumin binding and time action of acylated insulins in various species. J Pharra Sci JT - Journal of pharmaceutical sciences, 1996,85(3):304-8.
21 Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care JT - Diabetes care, 2005, 28(5): 1107-12.
22 Porcellati F, Rossetti P, Ricci Busciantella N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. Diabetes Care, 2007.
23 Kiess W, Raile K, Galler A, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care JT - Diabetes care, 2004, 27(10):2567-8.
24 Heise T, Nosek L, Ronn BB, et ak Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes JT - Diabetes, 2004, 53(6):1614-20.
25 Russell-Jones D. Insulin detemir: improving the predictability of glycaemic control. Int J Obes Relat Metab Disord JT - International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004,28 Suppl 2:S29-34.
26 Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2005, 7(1): 56-64.
27 Dornhorst A, Luddeke HJ, Honka M, et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin JT - Current medical research and opinion, 2008, 24(2):369-76.
28 Rosenstock J, Davies M, Home PD, et al. Arandomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia JT -Diabetologia, 2008, 51(3) :408-16.
29 Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003, 26(11):3080-6.
30 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005,28(4): 950-5.
31 Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care JT -Diabetes care, 2005, 28(4): 950-5.
32 Hamann A, Matthaei S, Rosak C, et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care JT - Diabetes care, 2003, 26(6): 1738-44.
33 Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol JT - European journal of clinical pharmacology, 2000, 56(5): 399-403.
34 Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care JT - Diabetes care, 1999,22(8): 1258-61.
35 Ligthelm RJ, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006,114(9) :511-9.
36 Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab JT -Diabetes, obesity & metabolism, 2006,8(1):58-66.
37 Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associatedwith lispro insulin in insulin pump therapy: an old complication, a new cause?. Diabetes Care JT - Diabetes care, 2001,24(1): 174.
38 Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy, is there any insulin preparation free of complications?. Diabetes Care JT - Diabetes care, 2003, 26(3) :953-4.
39 Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Diabetes Care JT - Diabetes care, 2005,28(12):2983.
40 Del Olmo MI, Campos V, Abellan P, et al. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract JT - Diabetes research and clinical practice, 2008.
41 Masson EA, Patmore JE, Brash PD, et al. Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2003,20(1):46-50.
42 . Scherbaum WA, Lankisch MR, Pawlowski B, et al. Insulin Lispro in pregnancy—retrospective analysis of 33 cases and matched controls. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2002,110(1) :6-9.
43 Boskovic R, Feig DS, Derewlany L, et al. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care JT - Diabetes care, 2003, 26(5):1390-4.
44 Bhattacharyya A, Brown S, Hughes S, et al. Insulin lispro and regular insulin in pregnancy. QJM JT - QJM : monthly journal of the Association of Physicians, 2001, 94(5):255-60.
45 Kitzmiller JL. Insulin lispro and the development of Proliferative diabetic retinopathy during pregnancy. Am J Obstet Gynecol JT - American journal of obstetrics and gynecology, 2001, 185(3):774-5.
46 Buchbinder A, Miodovnik M, McElvy S, et al. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?. Am J Obstet Gynecol JT - American journal of obstetrics and gynecology, 2000,183(5): 1162-5.
47 Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med JT - Annals of internal medicine, 2005,143(8):549-58.
48 Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care JT - Diabetes care, 2007, 30(4): 771-6.
49 Gallen IW, Jaap A, Roland JM, et al. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med JT - Diabetic medicine : a journal of the British Diabetic Association, 2008, 25(2):165-9.
50 Rachmiel M, Perlman K, Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am JT - Pediatric clinics of North America, 2005, 52(6):1651-75.
51 Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)—I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet JT - Lancet, 2004, 363(9418):1346-53.
52 Le Roith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev JT - Diabetes/metabolism research and reviews, 2007, 23(8):593-9.
53 Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care JT - Diabetes care, 2006, 29(3):554-9.
54 Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care, 2005, 28(2):254-9.
55 Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care, 2005,28(2):260-5.
56 Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med JT - Annals of internal medicine, 2005,143 (8): 559-69.
57 Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther JT -Clinical therapeutics, 2007,29(11): 2333-48.
58 Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol JT - Acta diabetologica, 2008, 45(1):53-9.
59 Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther JT - Clinical therapeutics, 2007, 29(11):2349-64.
60 Glass LC, Qu Y, Lenox S, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin, 2008.
61 Schreiber SA, Ferlinz K, Haak T. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technol Ther JT - Diabetes technology & therapeutics, 2008,10(2): 121-7.
62 Kawamori R, Eliaschewitz FG, Takayama H, et al. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract JT -Diabetes research and clinical practice, 2008, 79(1):97-102.
63 Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care JT - Diabetes care, 2001,24 (7): 1226-32.
64 Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther JT - Clinical therapeutics, 2007,29 Spec No:1236-53.
65 Janka HU, Hessel F, Walzer S, et al. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). Int J Clin Pharmacol Ther JT - International journal of clinical pharmacology and therapeutics, 2007,45(12): 623-30.
66 Simons WR, Vinod HD, Gerber RA, et al. Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. Exp Clin Endocrinol Diabetes JT - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006,114(9): 520-6.
67 Zheng L, Buchanan TA, Hodis HN, et al. Time from diagnosis of type 2 diabetes to initiation of insulin therapy is related to carotid artery intima-media thickness. Atherosclerosis JT - Atherosclerosis, 2003,170(2): 293-9.
68 Bogdanski P, Pupek-Musialik D, Dytfeld J, et al. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther JT - International journal of clinical pharmacology and therapeutics, 2007, 45(10):563-7.
69 Origin Trial Investigators, Gerstein H, Yusuf S, et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J JT - American heart journal, 2008,155(1):26-32, 32. e1-6.
70 Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care JT - Diabetes care, 2004, 27(10): 2356-62.
71 Cefalu WT. Inhaled insulin: a proof-of-concept study. Ann Intern Med JT - Annals of internal medicine, 2001,134(9 Pt 1):795.
72 Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med JT - Annals of internal medicine, 2001,134(3):203-7.
73 Skyler JS, Jovanovic L, Klioze S, et, al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care JT - Diabetes care, 2007,30(3):579-85.
74 Barnett AH, Lange P, Dreyer M, et al. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract JT - International journal of clinical practice, 2007,61 (10): 1614-25.
75 Liu MC, Riese RJ, Van Gundy K, et al. Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. Eur Respir J JT - The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology, 2008.
76 Keegan A. Exit Exubera. Inhalable insulin is withdrawn due to weak sales. Diabetes Forecast JT - Diabetes forecast, 2007,60(13): 19.
77 Black C, Cummins E, Royle P, et al. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess JT - Health technology assessment (Winchester, England), 2007,11(33):1-126.